Needham & Company Starts CTI BioPharma (CTIC) at Buy

March 26, 2018 7:02 AM

Needham & Company initiates coverage on CTI BioPharma (NASDAQ: CTIC) with a Buy rating and a price target of $10.00.Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found